Format

Send to

Choose Destination
Genome Med. 2017 Sep 25;9(1):85. doi: 10.1186/s13073-017-0475-4.

Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic.

Author information

1
Centre for Law and Genetics, Faculty of Law, University of Tasmania, Hobart, 7001, Australia. Dianne.Nicol@utas.edu.au.
2
Centre for Law and Genetics, Faculty of Law, University of Tasmania, Hobart, 7001, Australia.
3
Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford, Oxford, OX2 7DD, UK.
4
Innovation Center for Law and Technology, New York Law School, New York, 10013, USA.
5
Menzies Institute for Medical Research, University of Tasmania, Hobart, 7000, Australia.
6
Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, V5A1S6, Canada.
7
Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH8 9YL, UK.
8
Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology, Melbourne, 3122, Australia.
9
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, 2052, Australia.
10
School of Nursing and Midwifery, Flinders University, Adelaide, 5042, Australia.
11
Addgene, Cambridge, 02139, USA.
12
Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan.
13
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montreal, H3A0G4, Canada.
14
Department of Ethic, Graduate School of Letters, Kyoto University, Kyoto, 606-8501, Japan.
15
Faculty of Law, University of Cambridge, Cambridge, CB3 9DZ, UK.
16
Centre for Ophthalmology and Visual Science, University of Western Australia, Lions Eye Institute, Perth, 6009, Australia.
17
Sydney Health Ethics, Sydney School of Public Health, University of Sydney, Sydney, 2006, Australia.
18
Center for Translational Bioethics & Health Care Policy, Geisinger Health System, Danville, PA, 17822, USA.

Abstract

Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy.

PMID:
28946923
PMCID:
PMC5612325
DOI:
10.1186/s13073-017-0475-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center